Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Strosberg, Jonathan; El-Haddad, Ghassan; Wolin, Edward; Hendifar, Andrew; Yao, James; Chasen, Beth; Mittra, Erik; Kunz, Pamela L; Kulke, Matthew H; Jacene, Heather; Bushnell, David; O'Dorisio, Thomas M; Baum, Richard P; Kulkarni, Harshad R; Caplin, Martyn; Lebtahi, Rachida; Hobday, Timothy; Delpassand, Ebrahim; Van Cutsem, Eric; Benson, Al; Srirajaskanthan, Rajaventhan; Pavel, Marianne; Mora, Jaime; Berlin, Jordan; Grande, Enrique; Reed, Nicholas; Seregni, Ettore; Öberg, Kjell; Lopera Sierra, Maribel; Santoro, Paola; Thevenet, Thomas; Erion, Jack L; Ruszniewski, Philippe; Kwekkeboom, Dik; Krenning, Eric

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/32984

Title:	Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Authors:	Strosberg, Jonathan El-Haddad, Ghassan Wolin, Edward Hendifar, Andrew Yao, James Chasen, Beth Mittra, Erik Kunz, Pamela L Kulke, Matthew H Jacene, Heather Bushnell, David O'Dorisio, Thomas M Baum, Richard P Kulkarni, Harshad R Caplin, Martyn Lebtahi, Rachida Hobday, Timothy Delpassand, Ebrahim Van Cutsem, Eric Benson, Al Srirajaskanthan, Rajaventhan Pavel, Marianne Mora, Jaime Berlin, Jordan Grande, Enrique Reed, Nicholas Seregni, Ettore Öberg, Kjell Lopera Sierra, Maribel Santoro, Paola Thevenet, Thomas Erion, Jack L Ruszniewski, Philippe Kwekkeboom, Dik Krenning, Eric View more
Mesh:	Aged Antineoplastic Agents Delayed-Action Preparations Disease-Free Survival Drug Administration Schedule Female Gastrointestinal Neoplasms Humans Infusions, Intravenous Kaplan-Meier Estimate Male Middle Aged Nausea Neuroendocrine Tumors Octreotide Organometallic Compounds View more
Issue Date:	2017
Citation:	N. Engl. J. Med..2017 01;(376)2:125-135
Abstract:	Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors.
PMID:	28076709
URI:	https://hdl.handle.net/20.500.12530/32984
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC5895095.pdf		315.42 kB	Adobe PDF	View/Open

Show full item record